AN OPEN LABEL, BALANCED, RANDOMIZED, TWOTREATMENTS, SINGLE-PERIOD, SINGLE-DOSE, PARALLEL, COMPARATIVE SUBCUTANEOUS PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PEGINTERFERON ALFA-2b 1.5 MICROGRAMS/KG OF INTAS BIOPHARMACEUTICALS LTD., AHMEDABAD, INDIA WITH VIRAFERONPEG OF SCHERING CORPORATION IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS.

Trial Profile

AN OPEN LABEL, BALANCED, RANDOMIZED, TWOTREATMENTS, SINGLE-PERIOD, SINGLE-DOSE, PARALLEL, COMPARATIVE SUBCUTANEOUS PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PEGINTERFERON ALFA-2b 1.5 MICROGRAMS/KG OF INTAS BIOPHARMACEUTICALS LTD., AHMEDABAD, INDIA WITH VIRAFERONPEG OF SCHERING CORPORATION IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Hepatitis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Intas Biopharmaceuticals
  • Most Recent Events

    • 15 Feb 2012 Status changed from recruiting to completed Clinical Trials Registry - India.
    • 29 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top